Drug profile · INN
ceruletide diethylamine
TYMTRAN
ceruletide diethylamine (TYMTRAN) is a cholecystokinin a receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — ceruletide diethylamine
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
ceruletide diethylamine (TYMTRAN) is a cholecystokinin a receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Cholecystokinin A receptor agonist
Primary target: Cholecystokinin receptor type A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ceruletide diethylamine?
ceruletide diethylamine (TYMTRAN) is a cholecystokinin a receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ceruletide diethylamine?
TYMTRAN is a marketed brand name for ceruletide diethylamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceruletide diethylamine?
ceruletide diethylamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.